media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Dongyangguang Pharmaceutical’s protamine human insulin mixed injection (30R) pre-filled specification has been approved for marketing.

On April 9, 2026, Dongyangguang Pharmaceutical’s protamine human insulin mixed injection (30R) pre-filled specification officially received marketing approval from the National Medical Products Administration (NMPA) of China. This approval further enriches the company’s drug product pipeline in the field of diabetes and brings more and more convenient insulin medication options to diabetic patients in China. This product uses a classic premixed ratio of 30% soluble human insulin (short-acting) + 70% protamine human insulin (intermediate-acting). The dosage form and specifications are precisely matched to clinical needs, eliminating the need for frequent combination therapy, effectively simplifying treatment plans, helping patients achieve more stable blood glucose control, and improving their quality of life. ▶ Optimize insulin concentration and injection dosage scale: Precise blood sugar control It can match the individualized dosing needs of patients with different weights and blood glucose fluctuations, avoiding the inconvenience of large-dose injections and the dosage error problems when ...
- Source: drugdu
- 69
- April 17, 2026
Johnson & Johnson’s gusejinumab receives dual approval for a new indication, bringing a blockbuster new drug to psoriatic arthritis treatment

On April 16, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced on its website that Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson , had officially accepted two new marketing applications for gusejinumab injection (trade name: Tenoya®) for new indications (acceptance numbers: JXSS2600036 and JXSS2600037), both classified as Class 3.1 imported new drugs. This marks another important milestone for this world’s first IL-23 p19 targeted monoclonal antibody in China, signifying a comprehensive expansion of its indications and providing Chinese patients with autoimmune diseases with more comprehensive treatment options. picture From psoriasis to the entire autoimmune spectrum: the “Royal Path” of gasediumab. Gusekimumab is the world’s first approved monoclonal antibody targeting the IL-23 p19 subunit . By precisely blocking IL-23, a core “upstream” inflammatory factor in autoimmune diseases, it inhibits the inflammatory cascade response at its source and achieves long-term control of the disease. In ...
- Source: drugdu
- 71
- April 17, 2026
Potential BIC! Amoytop Biotech Introduces New Drug for Chronic Hepatitis B

On April 16, Amoytop Bio announced that it had signed a Licensing Agreement with Aligos Therapeutics, Inc. According to the agreement, Amoytop Bio will obtain an exclusive, non-transferable intellectual property license from Aligos to develop, manufacture, and commercialize Pevifoscorvir sodium ( also known as ALG-000184) in the licensed territories (Mainland China, Hong Kong SAR, Macao SAR, and Taiwan) and in the licensed fields (treatment, prevention, or relief of human hepatitis B virus infection or human hepatitis B virus/hepatitis D virus co-infection) , and will have the right to sublicense as stipulated in the agreement. In return, Amoytop Biotech will pay Aligos an upfront payment of US$25 million upon the agreement’s effective date , and will also pay regulatory milestone fees (up to US$85 million ), sales milestone fees (up to US$335 million ), and royalties calculated as a single-digit percentage of net sales, based on the progress of clinical and ...
- Source: drugdu
- 53
- April 17, 2026
Received $650 million RC148 down payment from AbbVie

On April 15th, Nanfang Finance News reported that Rongchang Biotechnology (09995.HK) issued a voluntary announcement stating that the company received a payment from AbbVie on April 15, 2026.The company has made an upfront payment of US$650 million for an exclusive licensing agreement for RC148. This agreement, effective March 10, 2026, grants AbbVie exclusive rights to develop, manufacture, and commercialize RC148 (the company’s proprietary PD-1/VEGF bispecific antibody drug) outside of Greater China. Under the agreement, the company is also entitled to up to US$4.95 billion in subsequent milestone payments, as well as tiered royalties from net sales outside of Greater China. This payment marks a significant step forward in the company’s international collaborations, will substantially enhance its cash reserves and R&D capabilities, and will facilitate faster global clinical development and pipeline value realization. https://finance.eastmoney.com/a/202604153706015296.html
- Source: drugdu
- 51
- April 17, 2026
【EXPERT Q&A】Is a ventilator the same as an oxygen generator? What’s the difference?

Drugdu.com expert’s response: Ventilators and oxygen concentrators are different, with significant disparities in their functional positioning, working principles, applicable populations, output gases, usage scenarios, and equipment structures, as detailed below: Functional Positioning Ventilator: Primarily used to assist or replace a patient’s respiratory function, helping those unable to breathe autonomously or with inadequate respiratory function to complete breathing movements and maintain airway patency and respiratory function. It is suitable for patients with respiratory failure, apnea, and other respiratory dysfunctions. Oxygen Concentrator: Mainly used to increase the oxygen concentration in inhaled air, providing high-concentration oxygen to hypoxic patients to improve their hypoxic state. It is suitable for individuals who are hypoxic but have basically normal respiratory function, such as patients with chronic obstructive pulmonary disease (COPD) and heart failure. Working Principles Ventilator: It pushes air into the lungs through mechanical force, simulating the human breathing process and regulating the rhythm and depth ...
- Source: drugdu
- 75
- April 17, 2026
Maiweijian® (Denosumab Injection) New Indication Supplemental Application Accepted by NMPA

Maiwei Biopharmaceutical (688062.SH), an innovative biopharmaceutical company with a full-industry chain layout, announced that the National Medical Products Administration (NMPA) has accepted the supplemental application for adding indications for Maiweijian® (denosumab injection, R&D code: 9MW0321), independently developed by its wholly-owned subsidiary Taikang Biopharmaceutical , for the treatment of bone metastases of solid tumors and multiple myeloma (for the treatment of patients with bone metastases of solid tumors or multiple myeloma, to delay or reduce the risk of bone-related events (pathological fractures, spinal cord compression, bone radiotherapy or bone surgery)). Maiweijian® is the first denosumab biosimilar (120mg) approved for marketing in China . It was first approved in March 2024 for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection would result in severe functional impairment, including adults and skeletally mature (defined as at least one mature long bone and a weight ≥45kg) adolescents. In ...
- Source: drugdu
- 71
- April 16, 2026
The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders.

Luye Pharma (02186.HK) issued a voluntary announcement stating that its independently developed innovative drug…The first subject has been enrolled in the Phase II clinical trial in China of LY03017 for the treatment of psychotic disorders in Alzheimer’s disease. LY03017 is a new-generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, with target indications including psychotic disorders in Alzheimer’s disease, psychotic disorders in Parkinson’s disease, and negative symptoms of schizophrenia. This Phase II clinical trial is a randomized, double-blind, parallel, placebo-controlled study designed to evaluate the preliminary efficacy and safety of LY03017 in treating hallucinations and delusions associated with Alzheimer’s disease; the drug has previously been approved for clinical trials in the United States. Background: Of the approximately 57 million dementia patients worldwide, 60% to 70% have Alzheimer’s disease, of whom 25% to 50% experience psychotic symptoms. Currently, there are no approved drugs worldwide for this indication. The Phase I clinical trial of ...
- Source: drugdu
- 69
- April 16, 2026
The first subject has been enrolled in the Phase II clinical trial in China for its innovative drug LY03017, which is used to treat Alzheimer’s disease and psychotic disorders.

Nanfang Finance News, April 15th – Luye Pharma (02186.HK) issued a voluntary announcement stating that its independently developed innovative drug…The first subject has been enrolled in the Phase II clinical trial in China of LY03017 for the treatment of psychotic disorders in Alzheimer’s disease. LY03017 is a new-generation 5-HT2AR inverse agonist and 5-HT2CR antagonist, with target indications including psychotic disorders in Alzheimer’s disease, psychotic disorders in Parkinson’s disease, and negative symptoms of schizophrenia. This Phase II clinical trial is a randomized, double-blind, parallel, placebo-controlled study designed to evaluate the preliminary efficacy and safety of LY03017 in treating hallucinations and delusions associated with Alzheimer’s disease; the drug has previously been approved for clinical trials in the United States. Background: Of the approximately 57 million dementia patients worldwide, 60% to 70% have Alzheimer’s disease, of whom 25% to 50% experience psychotic symptoms. Currently, there are no approved drugs worldwide for this indication. ...
- Source: drugdu
- 62
- April 16, 2026
Its subsidiary’s Phase III clinical trial of “Vitamettrazil” has completed the enrollment of the first patient.

On April 15, China Biopharmaceutical (01177) issued an announcement stating that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has independently developed a Class 1 innovative drug.Vitacoltobayumab (development code: LM-302) is undergoing a Phase III registration clinical trial in combination with a PD-1 monoclonal antibody as first-line treatment for CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, and the first patient has been successfully enrolled. LM-302 has been included in the Breakthrough Therapy Program by the China National Medical Products Administration for multiple indications and has received orphan drug designation from the U.S. Food and Drug Administration. https://finance.eastmoney.com/a/202604153705999476.html
- Source: drugdu
- 62
- April 16, 2026
A multi-billion dollar market is fiercely competitive, with Huadong Medicine applying for marketing approval of its megglutinin weight loss product.

On the evening of April 14, Huadong Medicine (000963) issued an announcement stating that its wholly-owned subsidiary, Hangzhou Sino-American Huadong Pharmaceutical Jiangdong Co., Ltd., received an “Acceptance Notice” issued by the National Medical Products Administration (NMPA) for the acceptance of its application for marketing authorization of Smegglutide injection, which is applicable to long-term weight management in adult patients based on diet control and increased physical activity. Previously, Huadong Medicine’s application for marketing authorization of its semaglutide injection for the hypoglycemic indication had been formally accepted by the National Medical Products Administration (NMPA). The acceptance of its application for the weight loss indication signifies that the product is poised to further expand its clinical application scenarios, meeting diverse market demands while gradually unlocking its long-term growth potential in chronic disease management and weight control. Smegglutide injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. ...
- Source: drugdu
- 59
- April 16, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.